A Novel Mimetic Peptide for Reducing Cardiovascular Disease

Back to search results
Atherosclerosis is a leading cause of death worldwide. Current atherosclerosis treatments lower plasma low density lipoprotein cholesterol (LDL-C) levels. However, as optimal LDL-C levels are not always achieved, and residual risk is often present even when very low LDL-C levels are achieved, it is clear that new therapeutic approaches are needed. We have developed a novel peptide, C-II-a, that fills this gap. Preliminary in vitro experiments show that C-II-a is cardioprotective. The project will use state-of-the art molecular and imaging approaches to establish that C-II-a reduces atherosclerosis in animals, and improves human atherosclerotic lesion composition and stability.

The ideal candidate for this project will be highly motivated and passionate about translating basic scientific observations into a preclinical, and ultimately a clinical setting. Previous experience in cell culture, small animal handling and imaging are desirable. High level analytical and written and oral communication skills are essential.

Supervisory team
Kerry-Anne
Rye

Medicine
Medical Sciences
Blake
Cochran

Medicine
Medical Sciences
Leonard
Kritharides

University of Sydney
Anzac Research Institute/Concord Hospital
k.rye@unsw.edu.au